A Comparison of Patients on AVAMYS ® Versus NASONEX (A Trade Mark of Schering Corporation) and FLIXONASE ® on Key Health Outcome Measures

• Status: Completed
• Trial end date: 2009-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Previous publications have indicated that Allergic Rhinitis (AR) patients suffering from both ocular and nasal symptoms have a greater burden of illness and lower quality of life than patients suffering from nasal symptoms alone. Fluticasone furoate (FF) acts against both nasal and ocular symptoms. The purpose of this study was to evaluate the differences in symptom control (both perceptually and objectively) and resource use for patients with current seasonal AR.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Collaborator: Adelphi Real World
• Treatments: Fluticasone; Mometasone Furoate; Xhance

Criteria

Patient Inclusion Criteria:

• Current Seasonal Allergic Rhinitis sufferer (based on physician judgement)

• Currently receiving prescribed INS treatment (no other treatment restrictions apply)

• Have consumed at least one full prescription on the specified INS treatment

• No comorbid Asthma or COPD diagnosis

• Informed Consent

Exclusion Criteria:

• None specified